Type your paragraph here.
Good News!
Hans Clevers' Lab has proved that our purified Wnt3a works very well for both human duodenum and colon organoids
Type your paragraph here.
What We’re Doing
Company Profile
Company Profile
Management Team
We are doing small things in a great way
Management Team
Copyright 2015. Time Bioscience. All Rights Reserved.
Founder and CEO: Tom Shi
Time Bioscience is non-profit biotech company specialized in the Wnt signaling, which is located in MBI in the Bioengineer Department Building of WPI.
The company was founded by Tom Shi, Ph.D. and Martha Hadeler, MBA in January 2015. The company is engaged in Wnt signaling pathway related drug discovery.
Time Bioscience is biotech company specialized in the Wnt signaling. The company was founded by Tom Shi, Ph.D. and Martha Hadeler, MBA. The company manufactures the Wnt signaling pathway drug discovery systems. The company also provides drug/compound screening services, custom protein manufacturing, as well as animal model services.
CEO, Tom Shi, Ph.D., Pharm.D.
Tom is a Harvard- and Yale-trained researcher. He has led drug discovery research targeting Wnt signaling pathway and led research to understand the pathogenesis of a variety of disorders. Prior to this position, he worked as scientist at Seaside Therapeutics where he led research effort to understand the role of inflammation in Hematopoiesis. Prior to Seaside Therapeutics, he led cancer drug discovery targeting Wnt signaling pathway at Yale University School Medicine. Before Yale, he completed his postdoctoral training at Harvard Medical School, led research to improve understanding of the pathogenesis of Lung Allergy and Tissue Injury.
CFO, Martha Hadeler, MBA
Martha is a senior finance executive, entrepreneur and portfolio manager with over three decades of experience in corporation management and investment and management. Her expertise includes strategic planning, business development, marketing, and financial management. She is accustomed to working in a highly regulated environment in which developing and complying with high standards is essential. Together with partners, she started and managed a successful investment management company, registered with the SEC, with $4 billion in assets under management, which she sold in 2010. Since that time she has been acting as an adviser to various companies and has been an active investor.